LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DIAsource ImmunoAssays SA Acquires Viro-Immun Diagnostics

By LabMedica International staff writers
Posted on 19 Sep 2017
Print article
DIAsource ImmunoAssays SA (Louvain-La-Neuve, Belgium), which develops, sells and distributes clinical diagnostics products, has acquired Viro-Immun Diagnostics GmbH (Viro-Immun Diagnostics GmbH), a developer and manufacturer of laboratory diagnostics for the medical diagnosis of infectious and autoimmune diseases.

DIAsource manufactures and sells manual kits and open automation for clinical diagnostics, while Viro-Immun offers a portfolio of assays in infectious and autoimmune diseases, including the ToRCH panel with parameters such as Toxoplasma, Rubella, Herpes. With this transaction, DIAsource has acquired the Viro-Immun brand name and all ELISA and IFA products, as well as full inventory and infrastructure, thereby further strengthening and extending its portfolio of endocrinology and Vitamin D products. The acquisition of Viro-Immun fits in with DIAsource's strategy to act as a consolidator in its core business of manual kits and open automation.

Effective September 5, 2017, BioVendor - Laboratornímedicínaa.s. (Brno, Czech Republic) acquired 100% of the shares of DIAsource from Anteo Diagnostics (Queensland, Australia), which had acquired DIAsource in January 2016. The acquisition of DIAsource extended BioVendor’s broad panel of ELISA and RIA assays, antibodies and reagents for clinical diagnostics, as well as established a direct sales presence in Belgium, France and Spain, and a worldwide network of over 100 sales and distribution partners in over 70 countries.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more